Baker Julian's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Aug 22, 2024
- Accession no.
- 0000950170-24-099827
- Filed
- Aug 22, 2024, 4:03 PM ET
- Trade date
- Aug 20-21, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $46.41. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director |
| Baker FelixCIK 0001087940 | Director |
| Baker Bros. Advisors LPCIK 0001263508 | Director |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director |
| 667, L.P.CIK 0001551139 | Director |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2024 | Common Stock | PPurchaseAcquired | +1 | $46.41 | +$46.41 | 5,516,986 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2024 | Common Stock | PPurchaseAcquired | +347,572 | $40.75 | +$14,163,524.24 | 919,001 | Indirect | |
| Aug 21, 2024 | Common Stock | PPurchaseAcquired | +2,246,587 | $40.75 | +$91,548,195.59 | 9,625,653 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC is a director of Kymera Therapeutics, Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.